Pair Name	Theaflavin 3,3'-digallate, Trastuzumab
Partner Name	Theaflavin 3,3'-digallate
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Mitosis
Gene Regulation	Down-regulation	Phosphorylation	MISP	hsa126353
	Down-regulation	Expression	PLK1	hsa5347
	Down-regulation	Expression	SHCBP1	hsa79801
In Vitro Model	NCI-N87	Gastric tubular adenocarcinoma	Homo sapiens (Human)	CVCL_1603
	HGC-27	Gastric carcinoma	Homo sapiens (Human)	CVCL_1279
	MKN45	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0434
	AGS	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0139
	KATO II	Down syndrome	Homo sapiens (Human)	CVCL_M882
	Hs 746.T	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0333
	HEK293T	Healthy	Homo sapiens (Human)	CVCL_0063
	SNU-216	Gastric tubular adenocarcinoma	Homo sapiens (Human)	CVCL_3946
Result	These findings suggest an aberrant mitotic HER2-SHCBP1-PLK1 axis underlies trastuzumab sensitivity and offer a new strategy to combat gastric cancer.

Pair Name	Resveratrol, Trastuzumab
Partner Name	Resveratrol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	ERBB2	hsa2064
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	T-47D	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0553
Result	Herceptin/resveratrol and herceptin/didox combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.

Pair Name	Lanatoside C, Trastuzumab
Partner Name	Lanatoside C
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	ERBB2	hsa2064
In Vitro Model	NCI-N87	Gastric tubular adenocarcinoma	Homo sapiens (Human)	CVCL_1603
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vivo Model	NCI-N87 cells (5×10⁶/mouse/0.1 ml) were injected subcutaneously into the dorsal right flank of 6-week-old BALB/c nude mice.
Result	Our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.

Pair Name	Gossypol, Trastuzumab
Partner Name	Gossypol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Expression	PIK3CA	hsa5290
In Vitro Model	SK-BR-3	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0033
	MDA-MB-453	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0418
Result	The trastuzumab/AT-101 combination may be a good candidate for patients with trastuzumab-resistant Her2-positive breast cancer and inhibition of the PI3K/AKT pathway may be one of the underlying mechanisms.